Search
for
Sort by
Research 241–270 of 287
- Alopecia in patients treated with molecularly targeted anticancer therapies
- Dermatologic adverse events associated with chemotherapy and targeted anticancer therapy
- Adverse Hair Reactions to New Targeted Therapies for Cancer
- The pharmacovigilance analysis of adverse events of erlotinib based on the open access FAERS database
- Androgen receptors and their biology
- The Use of Oral Dutasteride, Minoxidil, and Finasteride for Treating Endocrine Therapy-Induced Hair Loss from Breast Cancer Treatment: A Case Series Study
- EGFR inhibitor-induced folliculitis decalvans: a case series and management guidelines
- Alopecia totalis successfully treated with modified platelet-rich plasma therapy in a patient recalcitrant to traditional treatment modalities
- Headcover and male-pattern hair loss: A cross-sectional study
- First National Chemotherapy Safety Standards Issued Jointly by ASCO & ONS
- Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930
- Trastuzumab Induced Chemobrain, Atorvastatin Rescued Chemobrain with Enhanced Anticancer Effect and without Hair Loss-Side Effect
- ONCO-NK-TRANSITION-GM1: The Bridge Cancer Therapy Manufacturable by Current Pharmaceutical Industry — 60-80% Cure Rate — $50 per Dose A Complete Transitional Drug from Full N‑K GM Series to Current Pharma Capability
- ONCO-NK-TRANSITION-GM1: The Bridge Cancer Therapy Manufacturable by Current Pharmaceutical Industry — 60-80% Cure Rate — $50 per Dose A Complete Transitional Drug from Full N‑K GM Series to Current Pharma Capability
- PROTACs in 2025: from the laboratory concept to clinical breakthrough
- Antibody Drug Conjugates
- Abstract ED05-04: Presurgical models to effectively screen preventive agents
- Epidermal Growth Factor Receptor Regulates Skin Nerve Outgrowth and Branching
- First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors
- BRAF Inhibitor Dabrafenib in Patients with Metastatic <i>BRAF</i>-Mutant Thyroid Cancer
- The ophthalmological complications of targeted agents in cancer therapy: what do we need to know as ophthalmologists?
- Targeted expression of activated erbB-2 to the epidermis of transgenic mice elicits striking developmental abnormalities in the epidermis and hair follicles.
- Cutaneous toxicity as a predictive biomarker for clinical outcome in patients receiving anticancer therapy
- Genetically modified laboratory mice with sebaceous glands abnormalities
- Current and prospective strategies for advancing the targeted delivery of CRISPR/Cas system via extracellular vesicles
- Regenerative Medicine Therapy in Malaysia: An Update
- Enriching Proteolysis Targeting Chimeras with a Second Modality: When Two Are Better Than One
- Volume imaging to interrogate cancer cell-tumor microenvironment interactions in space and time
- Enzyme Inhibitors from Gorgonians and Soft Corals
- Inhaled Medicines for Targeting Non-Small Cell Lung Cancer